Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
Introduction
Microbiome therapeutics market is expected to grow at a kegher of more than 38 percent between now and 2030. A number of microbiome therapeutic companies have recently struggled or altogether shuttered for D pharma, Evalo, Finch, and Colido come to mind. Matt Pillar talks with the founder and CEO of a company that's weathered the regulatory storm.
Play episode from 00:00
Transcript
